scientifyRESEARCH
research funding database

RESEARCH FUNDING

This opportunity is currently closed.

Sign up for Content alerts to stay informed when this or related funding opportunities are posted.

Junior Investigator Global ATTR Cardiac Amyloidosis Research (France, Italy, Spain, Germany, Japan, Canada, Australia and South Korea)

Share this post

funding consultation boking
Text on a blue background says "Want to find funding & get support for grant-writing?" Logos of scientifyRESEARCH & GrantDesk appear below on a white background and an orange play symbol appears between the two logos. An arrow mark points to the logos.

The Junior Investigator Global ATTR Cardiac Amyloidosis Research from Pfizer supports early-career principal investigators in France, Italy, Spain, Germany, Japan, Canada, Australia and South Korea working on ATTR cardiac amyloidosis. The grant seeks to fund projects on:

  • Approaches for the early identification and follow up of ATTR cardiac amyloidosis patients
  • RW efficacy and safety of tafamidis in the clinical setting for the management of ATTR cardiac amyloidosis
  • Evaluation of patients with ATTR-CM presenting with a mixed phenotype (e.g. cardiomyopathy and polyneuropathy)

The applicant must be affiliated with a research institution in France, Italy, Spain, Germany, Japan, Canada, Australia or South Korea and have obtained their terminal degree within the past 10 years. Applicants may apply for up to 100,000 USD/year in funding support (including up to 28% of overheads) for 1-2 years.

Applications close on May 6, 2024.

The grant has closed Sign-up for our content alerts to be updated when it re-opens.

Adverts. Premium members do not see Google Ads.

Please Login / Subscribe to our premium membership to see the content. Sign up to Free trial to see detailed funding information.

non member

We value your opinion

Complete our 1-min user survey and receive complimentary full access to our premium research funding database.

Sign-up for our monthly
research funding newsletter

you can unsubscribe at any time